Hospital Universitario Vall d´Hebron. Barcelona.

Ensayo 1:
PACIENTES
HCC avanzado 2L
ENSAYO
“The GOING Study: Regorafenib followed by Nivolumab in patients with Hepatocellular Carcinoma progressing under sorafenib”
Tratamiento (Brazos)
Regorafenib + Nivolumab
INFORMACION ADICIONAL
Tolerantes Sorafenib
Ensayo 2:
PACIENTES
HCC avanzado 2L
ENSAYO
Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)
Tratamiento (Brazos)
Cabozantinib
INFORMACION ADICIONAL
Intolerantes a Sorafenib
Ensayo 3:
PACIENTES
Adyuvancia tras tratamiento curativo (cirugía o RF)
ENSAYO
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)
Tratamiento (Brazos)
Pembrolizumab vs placebo
INFORMACION ADICIONAL

Ensayo 4:
PACIENTES
HCC avanzado 1L
ENSAYO
ML42600: A PHASE IIIB, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB IN COMBINATION WITH BEVACIZUMAB TO INVESTIGATE SAFETY AND EFFICACY IN SPANISH PATIENTS WITH UNRESECTABLE OR UNSUITABLE FOR LOCOREGIONAL TREATMENTS HEPATOCELLULAR CARCINOMA NOT PREVIOUSLY TREATED WITH SYSTEMIC THERAPY.
Tratamiento (Brazos)
Atezolizumab + bevacizumab (brazo único)
INFORMACION ADICIONAL

Ensayo 5:
PACIENTES
HCC avanzado 1L
ENSAYO
MK-1308A-004: A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK 1308A (Coformulated MK 1308/MK 3475) in Combination with Lenvatinib (E7080/MK 7902) in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma.
Tratamiento (Brazos)
MK 1308A + Lenvatinib
INFORMACION ADICIONAL

Ensayo 6:
PACIENTES
HCC avanzado 1L
ENSAYO
CA209-9DW: A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma.
Tratamiento (Brazos)
Nivolumab + Ipilimumab, Sorafenib or Lenvatinib
INFORMACION ADICIONAL

Ensayo 7:
PACIENTES
HCC avanzado 2L (tras antiPD1/PDL1)
ENSAYO
21469 (BAYER): An Open-Label Study (Phase 2) of Regorafenib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Hepatocellular Carcinoma after PD-1/PD-L1 Immune Checkpoint Inhibitors.
Tratamiento (Brazos)
Regorafenib + Pembrolizumab
INFORMACION ADICIONAL

Ensayo 8:
PACIENTES
HCC avanzado 2L post atezo-beva
ENSAYO
MO42541: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS LENVATINIB OR SORAFENIB ALONE IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH ATEZOLIZUMAB AND BEVACIZUMAB
Tratamiento (Brazos)
Atezolizumab + Lenvatinib or Sorafenib, Lenvatinib or Sorafenib
INFORMACION ADICIONAL

Ensayo 9:
PACIENTES
Adyuvancia post cirugía o ablación
ENSAYO
WO41535: A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AT HIGH RISK OF RECURRENCE AFTER SURGICAL
Tratamiento (Brazos)
Atezolizumab + bevacizumab, Vigilancia activa
INFORMACION ADICIONAL

Ensayo 10:
PACIENTES

ENSAYO
[71]
Tratamiento (Brazos)

INFORMACION ADICIONAL

Visit Us On FacebookVisit Us On TwitterVisit Us On YoutubeVisit Us On LinkedinVisit Us On Instagram
});